Your browser doesn't support javascript.
loading
Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials / 中华医学杂志(英文版)
Chinese Medical Journal ; (24): 345-351, 2012.
Artigo em Inglês | WPRIM | ID: wpr-262612
ABSTRACT
<p><b>BACKGROUND</b>Invasive fungal infections such as candidiasis and mold infections cause significant morbidity and mortality in seriously ill patients. Micafungin is an echinocandin antifungal agent with potent activity against most species of Candida and Aspergillus. We did this meta-analysis to clarify whether micafungin offers superior efficacy and safety compared with other antifungal agent for treating infections associated with invasive candidiasis.</p><p><b>METHODS</b>We did a meta-analysis of randomized controlled trials to examine whether micafungin has superior efficacy and safety compared with other antifungal agents recommended by the treatment guidelines for fungal infection. Seven trials involving 2913 patients were included in this analysis. Odds ratios (OR) and 95% confidence intervals (CI) were calculated.</p><p><b>RESULTS</b>Micafungin was associated with significantly better treatment success compared with the comparator antifungal agents (modified intention to treat, 2851 patients; random-effects model, OR 1.20, 95%CI 1.00 - 1.45, P = 0.0487). In addition, micafungin was more effective than the comparators for antifungal prophylaxis of neutropenic patients undergoing hematopoietic stem cell transplantation (OR 1.47, 95%CI 1.08 - 2.00, P = 0.01). Although there was no significant difference between the compared regimens in terms of the incidence of adverse drug effects (OR 0.94, 95%CI 0.77 - 1.11), fewer patients treated with micafungin withdrew from the studies because of adverse events (OR 0.64, 95%CI 0.44 - 0.94).</p><p><b>CONCLUSIONS</b>Micafungin has a good safety and tolerability profile, with an efficacy at least comparable to the other antifungal agents. Micafungin offers advantages over other agents for antifungal prophylaxis. Micafungin offers an appropriate alternative for antifungal prophylaxis rather than the treatment of invasive candida infections.</p>
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Ensaios Clínicos Controlados Aleatórios como Assunto / Resultado do Tratamento / Usos Terapêuticos / Tratamento Farmacológico / Equinocandinas / Lipopeptídeos / Candidíase Invasiva / Antifúngicos Tipo de estudo: Ensaio Clínico Controlado / Guia de Prática Clínica / Revisões Sistemáticas Avaliadas Limite: Humanos Idioma: Inglês Revista: Chinese Medical Journal Ano de publicação: 2012 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Ensaios Clínicos Controlados Aleatórios como Assunto / Resultado do Tratamento / Usos Terapêuticos / Tratamento Farmacológico / Equinocandinas / Lipopeptídeos / Candidíase Invasiva / Antifúngicos Tipo de estudo: Ensaio Clínico Controlado / Guia de Prática Clínica / Revisões Sistemáticas Avaliadas Limite: Humanos Idioma: Inglês Revista: Chinese Medical Journal Ano de publicação: 2012 Tipo de documento: Artigo